Article
Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations.
Cell reports methods - 27 Sept 2021
Choi Jaewon, Goulding Scott P, Conn Brandon P, McGann Christopher D, Dietze Jared L, Kohler Jessica, Lenkala Divya, Boudot Antoine, Rothenberg Daniel A, Turcott Paul J, Srouji John R, Foley Kendra C, Rooney Michael S, van Buuren Marit M, Gaynor Richard B, Abelin Jennifer G, Addona Terri A, Juneja Vikram R
Abstract excerpt
Oncogenic mutations in KRAS can be recognized by T cells on specific class I human leukocyte antigen (HLA-I) molecules, leading to tumor control. To date, the discovery of T cell targets from KRAS mutations has relied on occasional T cell responses in patient samples or the use of transgenic mice. To overcome these limitations, we have developed a systematic target discovery and validation pipeline. We evaluate...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.